Efrat Dvash Riesenfeld

A leading scientist with PhD in Molecular Genetics from the Weizmann Institute of Science (2015) as well as a food and biotechnology engineer (Technion, 2005). Was awarded an American Diabetes Association fellowship and conducted postdoctoral research at Harvard Medical School (2018). Was the Director of Breast Cancer Translational Research Laboratory at Tel Aviv Sourasky Medical Center (Ichilov Hospital). At present, the CTO at Bee-io Honey Ltd. More than 17 years of academic research and management experience in the area of molecular genetics, cancer research, immunometabolism, chemotherapy, biotechnology, food engineering as well as project and people management. Passionate about novel scientific ideas, enabling technologies and implementation of scientific ideas to develop a sustainable future for the world. 2021-present CTO at Bee-io Honey Ltd - https://bee-io.com/ October 2018- 2021- Director of Breast Cancer Translational Research Laboratory at Tel Aviv Sourasky Medical Center (Ichilov Hospital) September 2016- August 2018 Postdoctoral Fellow at Harvard Medical School April 2016- August 2016 Intern at the Weizmann Institute of Science 2015- April 2016 Post-doctoral fellow at the Weizmann Institute of Science 2009-2015 PhD. In Molecular Genetics at the Weizmann Institute of Science 2005-2008 M. Sc. In Genetics and Breeding at the Hebrew University of Jerusalem. Summa cum laude. 2001-2005 B. Sc. In Biotechnology and Food Engineering at the Technion. Patents: (1) PCT/IL2015/050183. INHIBITORS OF LEUKOTRIENE MEDIATED ACTIVITY FOR ALLEVIATING CHEMOTHERAPY SIDE EFFECTS AND STRESS INDUCED CELL DEATH. (2) PCT/IL2015/050183. INHIBITORS OF LEUKOTRIENE-MEDIATED ACTIVITY FOR TREATING SIDE EFFECTS OF STATIN THERAPY. (3) METHOD FOR DELAYING THE ONSET OF INSULIN DEPENDENCE IN DIABETIC SUBJECTS IL248491